EyeGate Pharma appoints Dr. Franz Obermayr as acting CEO alongside Stephen From stepping to Executive Chairman

– USA, MA –  EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), a clinical-stage company developing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced the appointment of EVP Clinical Development Dr. Franz Obermayr, Ph.D. as acting CEO effective February 1, 2021, succeeding Stephen From who will provide strategic support as Executive Chairman.

“This management transition reflects the evolution of EyeGate as we embark on initiating a robust clinical program that is moving beyond ophthalmology with the intent to extend into a broad range of therapeutic areas,” said Dr. Obermayr. “The recent acquisition of Panoptes transformed EyeGate’s pipeline, bringing PP-001, a clinical-stage, next-generation, best-in-class inhibitor of Dihydroorotate Dehydrogenase with a validated immune-modulating mechanism and potential best-in-class specificity and potency to avoid off-target side effects and safety issues. I’m honored to take the helm during this new phase of growth and look forward to working with Stephen From, the Board and EyeGate management to fully exploit the clinical potential of PP-001 while leveraging the promising preclinical and clinical data we generated through Panoptes’ PP-001 development program.”

Mr. From commented, “As Co-Founder and former CEO of Panoptes, Franz is uniquely suited to lead EyeGate as it prepares to expand beyond ophthalmology. Franz‘s proven track record as a biomedical industry executive with expertise in global strategy and clinical and regulatory development, paired with his strong scientific acumen, will be invaluable as we advance our expanded pipeline. I, along with the entire Board, look forward to working with Franz and our impressive leadership team as we evolve into the new EyeGate.”

About Dr. Franz Obermayr

Dr. Obermayr was previously the Co-Founder and CEO of Panoptes Pharma, a privately-held biotech company, which was acquired by EyeGate in 2020. Before joining the management team at EyeGate, Dr. Obermayr had a major role in the development, clinical milestones, and regulatory strategic efforts for the Company’s transformative asset, PP-001, which has two novel formulations. Before Panoptes, Dr. Obermayr was Head of Clinical Development at Nabriva Therapeutics AG, where he was responsible for all clinical programs – including Xenleta, which was approved by the U.S. Food and Drug Administration for community-acquired bacterial pneumonia in 2019. His earlier career involved various positions at GPC-Biotech, most recently as Director Drug Discovery. He also played a key role in the commercialization of these programs by managing large collaborations with pharmaceutical companies. Before GPC-Biotech, he completed his postdoctoral studies at the Max-Planck Institute for Immunobiology in Freiburg.

Dr. Obermayr earned his Ph.D. in biochemistry at the Imperial Cancer Research Fund in London.

About EyeGate

EyeGate is a clinical-stage pharmaceutical company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system. PP-001, EyeGate’s lead clinical-stage drug product, is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of Dihydroorotate Dehydrogenase with best-in-class picomolar potency and a validated immune-modulating mechanism designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. PP-001 has been developed in two clinical-stage ophthalmic formulations; PaniJect, an intravitreal injection for inflammatory diseases of the eye including posterior uveitis, and PaniDrop, a novel nanocarrier technology eye drop for ocular surface diseases such as viral conjunctivitis and dry eye disease. Intravenous and oral formulations are also in development for conditions outside the ocular space. Also, EyeGate is developing Ocular Bandage Gel, a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity. OBG, with unique properties that help hydrate and protect the ocular surface, is in clinical evaluation for patients undergoing photorefractive keratectomy surgery for corneal wound repair after refractive surgery and patients with punctate epitheliopathies as a result of dry eye.

For more information: https://www.eyegatepharma.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team